Compare BNL & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNL | DYN |
|---|---|---|
| Founded | 2007 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.9B |
| IPO Year | 2008 | 2020 |
| Metric | BNL | DYN |
|---|---|---|
| Price | $22.40 | $24.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $20.22 | ★ $37.00 |
| AVG Volume (30 Days) | 2.0M | ★ 2.6M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $454,138,000.00 | N/A |
| Revenue This Year | $7.93 | N/A |
| Revenue Next Year | $5.45 | N/A |
| P/E Ratio | $93.17 | ★ N/A |
| Revenue Growth | ★ 5.17 | N/A |
| 52 Week Low | $15.77 | $8.88 |
| 52 Week High | $23.10 | $25.00 |
| Indicator | BNL | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 62.09 | 63.30 |
| Support Level | $19.60 | $16.47 |
| Resistance Level | $23.10 | $24.52 |
| Average True Range (ATR) | 0.44 | 1.46 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 62.84 | 84.68 |
Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.